Medicago has competition . . .
Four companies areworking to transform protein-producing tobacco plants from a proof ofconcept to a demonstration of the capability. The next step will be todevelop full industrial processes for producing the proteins.
Thecompanies are Fraunhofer USA Center for Molecular Biotechnology inDelaware, Kentucky Bioprocessing in Owensboro, a consortium calledProject GreenVax, whose partners are the Texas A&M University systemand a Texas company called G-Con, and Medicago USA in North Carolina.
“They’re all using tobacco plants, and there’s a little variation onthe theme ... "
Good bet is Medicago gets taken out prior to phase 3 due to extreme cost, and people are rightly fearing, with this bumbling mgmt, that the takeout price will be not nearly what one would expect here
As a pharmaceuticalcompany with a candidate vaccine, Magill said, “all I can do is committo a Phase 3 [effectiveness] study in which I will have to enroll 10,000people over the course of about three years in order to … show that mynew vaccine in this case would be as good as the traditional egg-basedvaccine.
“So 10,000 people, three years, $100 million,” he said.
“We don’t see very oftenthat a response like this essentially creates a new industry. But we’llsee,” Magill said. “You still have to go through clinical trials … andwork through all the issues. But I would say initially things are quitepleasing and somewhat promising.”"
https://www.defense.gov/news/newsarticle.aspx?id=61520